Entelos is the leading provider of predictive biosimulation for drug discovery and development. We provide advanced biosimulation capabilities that make discovery more efficient and increase clinical success.
For over 15 years, we have enabled R&D organizations to predict better paths to success by simulating systems biology. Our solutions include mechanism-based, mathematical models; virtual patients and populations; biosimulation software; and biosimulation expertise.
Funding Rounds (3) - $14.6MUpdate
|Jul 1, 2015||PRNewswire UK All - Global ADME-Toxicology Testing Market 2015-2019 - Advances in Technology with Accelrys, Agilent Technologies, Bio-Rad Laboratories, Promega, Sigma Aldrich & Thermo Fisher Scientific Dominating|
|Jul 1, 2015||Business Wire - Research and Markets: Global ADME-Toxicology Testing Market 2015-2019 - Demand from Biotechnology and Pharmaceutical Companies|
|Apr 17, 2015||PRNewswire UK All - ADME-Toxicology Testing (In-Vivo, & In-Vitro) Market - Global Strategic Business Report 2015: Pharma Industry Renews Focus on Cost Optimization|
|Apr 17, 2015||Business Wire - Research and Markets: ADME-Toxicology Testing (In-Vivo, & In-Vitro) Market - Global Strategic Business Report 2015|
|Jun 21, 2013||PE HUB - Entelos Secures More Financing from Clearlake, Michaelson Capital|
|Jul 27, 2009||Venture Beat - Entelos pays up to $39M for Iconix Biosciences|
|Mar 6, 2006||PE HUB - PE Week Wire|
|May 27, 2005||PE HUB - PE Week Wire -- Friday, May 27|
2121 South El Camino Real
San Mateo, CA 94403